Prescription patterns and costs of acne/rosacea medications in Medicare patients vary by prescriber specialty
- PMID: 28651825
- PMCID: PMC5557700
- DOI: 10.1016/j.jaad.2017.04.1127
Prescription patterns and costs of acne/rosacea medications in Medicare patients vary by prescriber specialty
Abstract
Background: Prescription patterns for acne/rosacea medications have not been described in the Medicare population, and comparisons across specialties are lacking.
Objective: To describe the medications used for treating acne/rosacea in the Medicare population and evaluate differences in costs between specialties.
Methods: A cross-sectional study was performed of the 2008 and 2010 Centers for Medicare and Medicaid Services Prescription Drug Profiles, which contains 100% of Medicare part D claims.
Results: Topical antibiotics accounted for 63% of all prescriptions. Patients ≥65 years utilized more oral tetracycline-class antibiotics and less topical retinoids. Specialists prescribed brand name drugs for the most common topical retinoids and most common topical antibiotics more frequently than family medicine/internal medicine (FM/IM) physicians by 6%-7%. Topical retinoids prescribed by specialists were, on average, $18-$20 more in total cost and $2-$3 more in patient cost than the same types of prescriptions from FM/IM physicians per 30-day supply. Specialists (60%) and IM physicians (56%) prescribed over twice the rate of branded doxycycline than FM doctors did (27%). The total and patient costs for tetracycline-class antibiotics were higher from specialists ($18 and $4 more, respectively) and IM physicians ($3 and $1 more, respectively) than they were from FM physicians.
Limitations: The data might contain rare prescriptions used for conditions other than acne/rosacea, and suppression algorithms might underestimate the number of specialist brand name prescriptions.
Conclusion: Costs of prescriptions for acne/rosacea from specialists are higher than those from primary care physicians and could be reduced by choosing generic and less expensive options.
Keywords: Medicare; acne; antibiotics; cost of care; prescription drug costs; rosacea; topical retinoids.
Copyright © 2017 American Academy of Dermatology, Inc. Published by Elsevier Inc. All rights reserved.
Conflict of interest statement
Conflict of Interest Disclosure: Dr. Kaffenberger serves on the advisory board of Castle Biosciences and has received research funds from Eli Lilly, XBiotech, Celgene, and Biogen.
Figures
Similar articles
-
The cost of topical immunomodulator therapy in Medicare patients varies by prescriber specialty.J Am Acad Dermatol. 2017 May;76(5):925-931. doi: 10.1016/j.jaad.2016.11.052. Epub 2017 Feb 2. J Am Acad Dermatol. 2017. PMID: 28162853
-
Characterizing the relationship between free drug samples and prescription patterns for acne vulgaris and rosacea.JAMA Dermatol. 2014 May;150(5):487-93. doi: 10.1001/jamadermatol.2013.9715. JAMA Dermatol. 2014. PMID: 24740450 Free PMC article.
-
Prescribing Patterns and Costs Associated with Postoperative Eye Drop Use in Medicare Beneficiaries Undergoing Cataract Surgery.Ophthalmology. 2020 May;127(5):573-581. doi: 10.1016/j.ophtha.2019.11.005. Epub 2019 Nov 14. Ophthalmology. 2020. PMID: 31952884
-
Acne and rosacea. New and emerging therapies.Dermatol Clin. 2000 Jan;18(1):63-71, viii. doi: 10.1016/s0733-8635(05)70147-9. Dermatol Clin. 2000. PMID: 10626112 Review.
-
Drugs for acne, rosacea and psoriasis.Treat Guidel Med Lett. 2008 Nov;6(75):75-82. Treat Guidel Med Lett. 2008. PMID: 18948860 Review. No abstract available.
Cited by
-
Prescriber Phenotypes: Variability in Topical Rosacea Treatment Patterns Among United States Dermatologists.J Clin Med. 2024 Oct 21;13(20):6275. doi: 10.3390/jcm13206275. J Clin Med. 2024. PMID: 39458225 Free PMC article.
-
Comparative Efficacy of Pharmacological Treatments for Acne Vulgaris: A Network Meta-Analysis of 221 Randomized Controlled Trials.Ann Fam Med. 2023 Jul-Aug;21(4):358-369. doi: 10.1370/afm.2995. Ann Fam Med. 2023. PMID: 37487721 Free PMC article. Review.
-
Rosacea Topical Treatment and Care: From Traditional to New Drug Delivery Systems.Mol Pharm. 2023 Aug 7;20(8):3804-3828. doi: 10.1021/acs.molpharmaceut.3c00324. Epub 2023 Jul 21. Mol Pharm. 2023. PMID: 37478169 Free PMC article. Review.
-
Ocular Rosacea microBiome Study (ORBS)-sub-microbial versus antibiotic dosing of doxycycline versus placebo in treatment of symptomatic ocular rosacea: study protocol for a parallel-arm randomized clinical trial.Trials. 2022 Dec 20;23(1):1033. doi: 10.1186/s13063-022-06948-9. Trials. 2022. PMID: 36539810 Free PMC article.
References
-
- Davis SA, Feldman SR. Patterns of ambulatory care usage and leading treatments for rosacea. J Dermatolog Treat. 2014 Aug;25(4):275–277. - PubMed
-
- Romanowicz M, Stephenson JJ, Del Rosso JQ, Lenhart G. Healthcare utilization and costs of patients with rosacea in an insured population. J Drugs Dermatol. 2008 Jan;7(1):41–49. - PubMed
-
- Pena S, Hill D, Feldman SR. Use of topical retinoids by dermatologists and non-dermatologists in the management of acne vulgaris. J Am Acad Dermatol. 2016 Jun;74(6):1252–1254. - PubMed
-
- Bickers DR, Lim HW, Margolis D, et al. The burden of skin diseases: 2004 a joint project of the American Academy of Dermatology Association and the Society for Investigative Dermatology. J Am Acad Dermatol. 2006 Sep;55(3):490–500. - PubMed
-
- Barbieri JS, Hoffstad O, Margolis DJ. Duration of oral tetracycline-class antibiotic therapy and use of topical retinoids for the treatment of acne among general practitioners (GP): A retrospective cohort study. J Am Acad Dermatol. 2016 Dec;75(6):1142–1150. e1141. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
